Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.
Interferon beta (IFNbeta) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS). However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the serum and plasma of people with multiple sclerosis (M...
Main Authors: | Kaushal S Gandhi, Fiona C McKay, Eve Diefenbach, Ben Crossett, Stephen D Schibeci, Robert N Heard, Graeme J Stewart, David R Booth, Jonathan W Arthur |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2864746?pdf=render |
Similar Items
-
Beta-interferons in multiple sclerosis
by: Aggarwal Sourabh, et al.
Published: (2010-01-01) -
Neutralising antibodies to interferon beta in multiple sclerosis
by: Farrell, R. A.
Published: (2010) -
Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment
by: Monika Adamczyk-Sowa, et al.
Published: (2017-01-01) -
Higher Serum Uric Acid Levels in Multiple Sclerosis Patients After Longterm Interferon Beta Treatment
by: Toncev Gordana, et al.
Published: (2017-10-01) -
Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis
by: E Gibbons, et al.
Published: (2015-01-01)